🎉 M&A multiples are live!
Check it out!

Verve Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Verve Therapeutics and similar public comparables like Vivoryon Therapeutics, Julphar, and Pharming.

Verve Therapeutics Overview

About Verve Therapeutics

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.


Founded

2018

HQ

United States of America
Employees

274

Website

vervetx.com

Financials

LTM Revenue $30.0M

LTM EBITDA -$248M

EV

-$88.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Verve Therapeutics Financials

Verve Therapeutics has a last 12-month revenue of $30.0M and a last 12-month EBITDA of -$248M.

In the most recent fiscal year, Verve Therapeutics achieved revenue of $32.3M and an EBITDA of -$222M.

Verve Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Verve Therapeutics valuation multiples based on analyst estimates

Verve Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $11.8M $32.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$218M -$222M XXX XXX XXX
EBITDA Margin -1851% -686% XXX XXX XXX
Net Profit -$157M -$200M XXX XXX XXX
Net Margin -1339% -619% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Verve Therapeutics Stock Performance

As of April 15, 2025, Verve Therapeutics's stock price is $4.

Verve Therapeutics has current market cap of $366M, and EV of -$88.5M.

See Verve Therapeutics trading valuation data

Verve Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$88.5M $366M XXX XXX XXX XXX $-2.44

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Verve Therapeutics Valuation Multiples

As of April 15, 2025, Verve Therapeutics has market cap of $366M and EV of -$88.5M.

Verve Therapeutics's trades at -3.0x LTM EV/Revenue multiple, and 0.4x LTM EBITDA.

Analysts estimate Verve Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Verve Therapeutics and 10K+ public comps

Verve Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$88.5M XXX XXX XXX
EV/Revenue -2.7x XXX XXX XXX
EV/EBITDA 0.4x XXX XXX XXX
P/E -1.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Verve Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Verve Therapeutics Valuation Multiples

Verve Therapeutics's NTM/LTM revenue growth is -27%

Verve Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Verve Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Verve Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Verve Therapeutics and other 10K+ public comps

Verve Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 175% XXX XXX XXX XXX
EBITDA Margin -686% XXX XXX XXX XXX
EBITDA Growth 2% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -714% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 175% XXX XXX XXX XXX
R&D Expenses to Revenue 632% XXX XXX XXX XXX
Opex to Revenue 807% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Verve Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Verve Therapeutics M&A and Investment Activity

Verve Therapeutics acquired  XXX companies to date.

Last acquisition by Verve Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Verve Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Verve Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Verve Therapeutics

When was Verve Therapeutics founded? Verve Therapeutics was founded in 2018.
Where is Verve Therapeutics headquartered? Verve Therapeutics is headquartered in United States of America.
How many employees does Verve Therapeutics have? As of today, Verve Therapeutics has 274 employees.
Who is the CEO of Verve Therapeutics? Verve Therapeutics's CEO is Dr. Sekar Kathiresan, M.D..
Is Verve Therapeutics publicy listed? Yes, Verve Therapeutics is a public company listed on NAS.
What is the stock symbol of Verve Therapeutics? Verve Therapeutics trades under VERV ticker.
When did Verve Therapeutics go public? Verve Therapeutics went public in 2021.
Who are competitors of Verve Therapeutics? Similar companies to Verve Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Verve Therapeutics? Verve Therapeutics's current market cap is $366M
What is the current revenue of Verve Therapeutics? Verve Therapeutics's last 12-month revenue is $30.0M.
What is the current EBITDA of Verve Therapeutics? Verve Therapeutics's last 12-month EBITDA is -$248M.
What is the current EV/Revenue multiple of Verve Therapeutics? Current revenue multiple of Verve Therapeutics is -3.0x.
What is the current EV/EBITDA multiple of Verve Therapeutics? Current EBITDA multiple of Verve Therapeutics is 0.4x.
What is the current revenue growth of Verve Therapeutics? Verve Therapeutics revenue growth between 2023 and 2024 was 175%.
Is Verve Therapeutics profitable? Yes, Verve Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.